Skip to main content
Erschienen in: Obesity Surgery 12/2018

02.08.2018 | Original Contributions

Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis

verfasst von: Basile Njei, Thomas R. McCarty, Prabin Sharma, Andrew Lange, Nilofar Najafian, Julius N. Ngu, Valmy E. Ngomba, Justin B. Echouffo-Tcheugui

Erschienen in: Obesity Surgery | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The association between obesity and rising incidence of hepatocellular carcinoma (HCC) in the USA has been documented; however, the role of bariatric surgery remains less clear.

Aim

To evaluate the cross-sectional association of prior-bariatric surgery and HCC.

Methods

The United States Nationwide Inpatient Sample (NIS) database was queried from 2004 to 2014 for discharges with a diagnosis of morbid obesity. Primary outcomes of interest were HCC and in-hospital mortality rate. Secondary outcomes were length of stay and cost. Baseline characteristics were balanced using propensity score matching (PSM). Using Poisson and logistic regressions, adjusted HCC prevalence ratio (PR) and mortality odds ratio (OR) were derived in patients with prior-bariatric surgery compared to those without bariatric surgery.

Results

Of the 2,881,414 patients included in our study, 267,082 (9.3%) underwent bariatric surgery. From 2004 to 2014, there was a threefold increase in age-adjusted prevalence of HCC from 27 per 100,000 to 72 per 100,000 (PTrend < 0.001). After PSM, 230,956 patients with prior-bariatric surgery were matched with 230,956 patients without bariatric surgery. Prior-bariatric surgery was associated with lower prevalence of HCC (PR 0.11; 95% CI, 0.03–0.48; P < 0.001). In-hospital mortality was also lower for patients with surgery (OR 0.22; 95% CI, 0.20–0.26; P < 0.001). The occurrence of HCC added $18,840 extra cost, increased mean length of stay by 2 (95% CI; 1–3) days, and increased risk of death by 65% (aOR 1.65; 95% CI 1.18–2.29).

Conclusion

In this nationwide study of morbidly obese patients, prior-bariatric surgery was associated with a lower prevalence of HCC and lower in-patient mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRef El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRef
2.
Zurück zum Zitat El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.CrossRef El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.CrossRef
3.
Zurück zum Zitat Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRef Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRef
4.
Zurück zum Zitat El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–23.CrossRef El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–23.CrossRef
5.
Zurück zum Zitat Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.CrossRef Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.CrossRef
6.
Zurück zum Zitat Mitchell NS, Catenacci VA, Wyatt HR, et al. Obesity: overview of an epidemic. Psychiatr Clin N Am. 2011;34:717–32.CrossRef Mitchell NS, Catenacci VA, Wyatt HR, et al. Obesity: overview of an epidemic. Psychiatr Clin N Am. 2011;34:717–32.CrossRef
7.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRef Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRef
8.
Zurück zum Zitat Moller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994;30A:344–50.CrossRef Moller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994;30A:344–50.CrossRef
9.
Zurück zum Zitat Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12:13–21.CrossRef Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12:13–21.CrossRef
11.
Zurück zum Zitat Dudekula A, Rachakonda V, Shaik B, et al. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One. 2014;9:e111808.CrossRef Dudekula A, Rachakonda V, Shaik B, et al. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One. 2014;9:e111808.CrossRef
13.
Zurück zum Zitat Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005;93:1062–7.CrossRef Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005;93:1062–7.CrossRef
14.
Zurück zum Zitat Yang B, Yang HP, Ward KK, et al. Bariatric surgery and liver cancer in a consortium of academic medical centers. Obes Surg. 2016;26:696–700.CrossRef Yang B, Yang HP, Ward KK, et al. Bariatric surgery and liver cancer in a consortium of academic medical centers. Obes Surg. 2016;26:696–700.CrossRef
15.
Zurück zum Zitat Lam PH, Obirieze AC, Ortega G, et al. Characterization of hepatitis B and C among liver transplant recipients with hepatocellular carcinoma: an analysis of the nationwide inpatient sample database. Transplant Proc. 2016;48:123–7.CrossRef Lam PH, Obirieze AC, Ortega G, et al. Characterization of hepatitis B and C among liver transplant recipients with hepatocellular carcinoma: an analysis of the nationwide inpatient sample database. Transplant Proc. 2016;48:123–7.CrossRef
16.
Zurück zum Zitat McCarty TR, Echouffo-Tcheugui JB, Lange A, et al. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis. 2018;14:74–80.CrossRef McCarty TR, Echouffo-Tcheugui JB, Lange A, et al. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis. 2018;14:74–80.CrossRef
18.
Zurück zum Zitat Abbas A, Medvedev S, Shores N, et al. Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. Dig Dis Sci. 2014;59:2813–20.CrossRef Abbas A, Medvedev S, Shores N, et al. Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. Dig Dis Sci. 2014;59:2813–20.CrossRef
19.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRef
20.
Zurück zum Zitat Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172:1092–7.CrossRef Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172:1092–7.CrossRef
21.
Zurück zum Zitat Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761–7.CrossRef Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761–7.CrossRef
23.
Zurück zum Zitat Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.CrossRef Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.CrossRef
24.
Zurück zum Zitat Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8.CrossRef Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8.CrossRef
25.
Zurück zum Zitat Hassan MM, Abdel-Wahab R, Kaseb A, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149:119–29.CrossRef Hassan MM, Abdel-Wahab R, Kaseb A, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149:119–29.CrossRef
26.
Zurück zum Zitat Schutte K, Balbisi F, Malfertheiner P. Prevention of hepatocellular carcinoma. Gastrointest Tumors. 2016;3:37–43.CrossRef Schutte K, Balbisi F, Malfertheiner P. Prevention of hepatocellular carcinoma. Gastrointest Tumors. 2016;3:37–43.CrossRef
27.
Zurück zum Zitat Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704–13.CrossRef Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704–13.CrossRef
28.
Zurück zum Zitat Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 2016;61:1234–45.CrossRef Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 2016;61:1234–45.CrossRef
29.
Zurück zum Zitat Font-Burgada J, Sun B, Karin M. Obesity and Cancer: the oil that feeds the flame. Cell Metab. 2016;23:48–62.CrossRef Font-Burgada J, Sun B, Karin M. Obesity and Cancer: the oil that feeds the flame. Cell Metab. 2016;23:48–62.CrossRef
30.
Zurück zum Zitat Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol. 2016;22:394–406.CrossRef Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol. 2016;22:394–406.CrossRef
31.
Zurück zum Zitat Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35:191–202.CrossRef Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35:191–202.CrossRef
32.
Zurück zum Zitat Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006;5:259–69.CrossRef Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006;5:259–69.CrossRef
34.
Zurück zum Zitat Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRef Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRef
35.
Zurück zum Zitat Fischer L, Hildebrandt C, Bruckner T, et al. Excessive weight loss after sleeve gastrectomy: a systematic review. Obes Surg. 2012;22:721–31.CrossRef Fischer L, Hildebrandt C, Bruckner T, et al. Excessive weight loss after sleeve gastrectomy: a systematic review. Obes Surg. 2012;22:721–31.CrossRef
36.
Zurück zum Zitat Khan S, Rock K, Baskara A, et al. Trends in bariatric surgery from 2008 to 2012. Am J Surg. 2016;211:1041–6.CrossRef Khan S, Rock K, Baskara A, et al. Trends in bariatric surgery from 2008 to 2012. Am J Surg. 2016;211:1041–6.CrossRef
37.
Zurück zum Zitat O'Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16:1032–40.CrossRef O'Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16:1032–40.CrossRef
38.
Zurück zum Zitat Phillips E, Ponce J, Cunneen SA, et al. Safety and effectiveness of realize adjustable gastric band: 3-year prospective study in the United States. Surg Obes Relat Dis. 2009;5:588–97.CrossRef Phillips E, Ponce J, Cunneen SA, et al. Safety and effectiveness of realize adjustable gastric band: 3-year prospective study in the United States. Surg Obes Relat Dis. 2009;5:588–97.CrossRef
39.
Zurück zum Zitat Davila JA, El-Serag H. The rising incidence of hepatocellular carcinoma in the United States: an update. Gastroenterology. 2012;142(5):Supp 1:S–914.CrossRef Davila JA, El-Serag H. The rising incidence of hepatocellular carcinoma in the United States: an update. Gastroenterology. 2012;142(5):Supp 1:S–914.CrossRef
40.
Zurück zum Zitat Saunders D, Seidel D, Allison M, et al. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther. 2010;31:1051–63.PubMed Saunders D, Seidel D, Allison M, et al. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther. 2010;31:1051–63.PubMed
Metadaten
Titel
Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis
verfasst von
Basile Njei
Thomas R. McCarty
Prabin Sharma
Andrew Lange
Nilofar Najafian
Julius N. Ngu
Valmy E. Ngomba
Justin B. Echouffo-Tcheugui
Publikationsdatum
02.08.2018
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 12/2018
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3431-5

Weitere Artikel der Ausgabe 12/2018

Obesity Surgery 12/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.